Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00035321
Status:
COMPLETED
Last Update Posted:
2006-07-24
First Post:
2002-05-02
Brief Title:
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features
Status:
COMPLETED
Status Verified Date:
2006-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purposes of this study are to determine
Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression
The safety of olanzapine plus fluoxetine in combination plus and any side effects that might be associated with the combination
The effectiveness of olanzapine plus fluoxetine compared to olanzapine and fluoxetine alone
Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression
The safety of olanzapine plus fluoxetine in combination plus and any side effects that might be associated with the combination
The effectiveness of olanzapine plus fluoxetine compared to olanzapine and fluoxetine alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H6P-MC-HDAO | None | None | None |